Real time insider trading transaction history:
- Insiders are prohibited from making short-swing profits by trading their shares within 6 months of the registration or acquiring the shares.
- Shares are not adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
Common stock purchase or sale:
| Transaction Date |
Reported DateTime |
Company | Symbol | Insider Relationship |
Shares Traded |
Average Price |
Total Amount |
Shares Owned |
Filing |
| 2023-03-03 Sale |
2023-03-07 4:52 pm |
NovoCure Ltd | NVCR | Leonard Frank X President, CNS Cancers US |
13,609 | $75.55 | $1,028,165 | 54,284 (Direct) |
View |
| 2023-03-03 Sale |
2023-03-07 4:52 pm |
NovoCure Ltd | NVCR | Shah Pritesh Chief Growth Officer |
21,421 | $76.16 | $1,631,411 | 124,799 (Direct) |
View |
| 2023-03-03 Sale |
2023-03-07 4:51 pm |
NovoCure Ltd | NVCR | GROENHUYSEN WILHELMUS CM Chief Operating Officer |
25,635 | $76.16 | $1,952,346 | 209,753 (Direct) |
View |
| 2023-03-03 Sale |
2023-03-07 4:51 pm |
NovoCure Ltd | NVCR | Cordova Ashley Chief Financial Officer |
5,505 | $76.16 | $419,257 | 101,310 (Direct) |
View |
| 2023-03-03 Sale |
2023-03-07 4:50 pm |
NovoCure Ltd | NVCR | Burke William Patrick Chief Human Resources Officer |
593 | $76.16 | $45,163 | 66,090 (Direct) |
View |
| 2023-03-02 Sale |
2023-03-06 4:42 pm |
NovoCure Ltd | NVCR | Burke William Patrick Chief Human Resources Officer |
281 | $75.28 | $21,153 | 66,683 (Direct) |
View |
| 2023-03-02 Sale |
2023-03-06 4:41 pm |
NovoCure Ltd | NVCR | Shah Pritesh Chief Growth Officer |
937 | $75.28 | $70,535 | 146,220 (Direct) |
View |
| 2023-03-02 Sale |
2023-03-06 4:40 pm |
NovoCure Ltd | NVCR | GROENHUYSEN WILHELMUS CM Chief Operating Officer |
1,213 | $75.28 | $91,312 | 235,388 (Direct) |
View |
| 2023-03-02 Sale |
2023-03-06 4:40 pm |
NovoCure Ltd | NVCR | Cordova Ashley Chief Financial Officer |
1,055 | $75.28 | $79,418 | 106,815 (Direct) |
View |
| 2023-03-02 Sale |
2023-03-06 4:37 pm |
NovoCure Ltd | NVCR | Leonard Frank X President, CNS Cancers US |
2,903 | $76.95 | $223,393 | 67,893 (Direct) |
View |
| 2023-03-02 Sale |
2023-03-03 4:13 pm |
NovoCure Ltd | NVCR | Leonard Frank X President, CNS Cancers US |
4,107 | $75.38 | $309,578 | 58,988 (Direct) |
View |
| 2023-03-01 Sale |
2023-03-02 5:01 pm |
NovoCure Ltd | NVCR | Leonard Frank X President, CNS Cancers US |
1,684 | $76.36 | $128,594 | 94,066 (Direct) |
View |
| 2023-03-01 Sale |
2023-03-02 5:00 pm |
NovoCure Ltd | NVCR | Shah Pritesh Chief Growth Officer |
1,923 | $76.36 | $146,845 | 131,666 (Direct) |
View |
| 2023-03-01 Sale |
2023-03-02 4:55 pm |
NovoCure Ltd | NVCR | Cordova Ashley Chief Financial Officer |
2,198 | $76.36 | $167,845 | 135,676 (Direct) |
View |
| 2023-03-01 Sale |
2023-03-02 4:51 pm |
NovoCure Ltd | NVCR | Burke William Patrick Chief Human Resources Officer |
755 | $76.36 | $57,654 | 87,132 (Direct) |
View |
| 2023-03-01 Sale |
2023-03-02 4:49 pm |
NovoCure Ltd | NVCR | GROENHUYSEN WILHELMUS CM Chief Operating Officer |
2,164 | $76.36 | $165,248 | 220,628 (Direct) |
View |
| 2023-01-05 Sale |
2023-01-09 6:24 pm |
NovoCure Ltd | NVCR | Weinberg Uri Chief Science Officer |
8,143 | $116.14 | $945,756 | 45,232 (Direct) |
View |
| 2023-01-05 Sale |
2023-01-09 6:21 pm |
NovoCure Ltd | NVCR | Leonard Frank X President, CNS Cancers US |
39,507 | $112.25 | $4,434,654 | 74,299 (Direct) |
View |
| 2023-01-05 Sale |
2023-01-09 6:20 pm |
NovoCure Ltd | NVCR | Shah Pritesh Chief Commercial Officer |
387 | $108 | $41,796 | 82,843 (Direct) |
View |
| 2023-01-05 Sale |
2023-01-09 6:18 pm |
NovoCure Ltd | NVCR | Danziger Asaf Chief Executive Officer |
212,500 | $108.74 | $23,106,230 | 13,622 (Direct) |
View |
| 2022-10-13 Sale |
2022-10-17 4:35 pm |
NovoCure Ltd | NVCR | Leonard Frank X President, CNS Cancers US |
6,754 | $76.01 | $513,372 | 43,626 (Direct) |
View |
Stock options: Exercise, Award, Grant, Conversion
| Transaction Date |
Reported DateTime |
Exercisable Expiration |
Company | Symnbol | Insider Relationship |
Shares Traded |
Conversion Price |
Shares Owned |
Filing |
| 2023-06-07 Option Award |
2023-06-09 4:04 pm |
2024-06-07 2033-06-06 |
NovoCure Ltd | NVCR | Hung David Director |
12,554 | $0 | 12,554 (Direct) |
View |
| 2023-06-07 Option Award |
2023-06-09 4:04 pm |
2024-06-07 2033-06-06 |
NovoCure Ltd | NVCR | Madden Martin J. Director |
12,554 | $0 | 12,554 (Direct) |
View |
| 2023-06-07 Option Award |
2023-06-09 4:04 pm |
2024-06-07 2033-06-06 |
NovoCure Ltd | NVCR | LEUNG GABRIEL Director |
10,130 | $0 | 85,416 (Direct) |
View |
| 2023-06-07 Option Award |
2023-06-09 4:04 pm |
2024-06-07 2033-06-06 |
NovoCure Ltd | NVCR | HILLEMAN JERYL L Director |
12,554 | $0 | 12,554 (Direct) |
View |
| 2023-05-09 Option Award(A) |
2023-05-17 4:58 pm |
N/A 2033-05-08 |
NovoCure Ltd | NVCR | Stafford Kristin Director |
15,873 | $0 | 15,873 (Direct) |
View |
| 2023-05-09 Option Award |
2023-05-11 4:34 pm |
N/A 2033-05-08 |
NovoCure Ltd | NVCR | Stafford Kristin Director |
15,873 | $0 | 15,873 (Direct) |
View |
| 2023-03-03 Option Award |
2023-03-06 4:43 pm |
N/A N/A |
NovoCure Ltd | NVCR | Weinberg Uri Chief Innovation Officer |
32,766 | $0 | 89,044 (Direct) |
View |
| 2023-03-03 Option Award |
2023-03-06 4:41 pm |
N/A N/A |
NovoCure Ltd | NVCR | Shah Pritesh Chief Growth Officer |
47,182 | $0 | 146,220 (Direct) |
View |
| 2023-03-03 Option Award |
2023-03-06 4:40 pm |
N/A N/A |
NovoCure Ltd | NVCR | GROENHUYSEN WILHELMUS CM Chief Operating Officer |
51,986 | $0 | 235,388 (Direct) |
View |
| 2023-03-03 Option Award |
2023-03-06 4:40 pm |
N/A N/A |
NovoCure Ltd | NVCR | Cordova Ashley Chief Financial Officer |
11,808 | $0 | 106,815 (Direct) |
View |
| 2023-03-03 Option Award |
2023-03-06 4:37 pm |
N/A N/A |
NovoCure Ltd | NVCR | Leonard Frank X President, CNS Cancers US |
11,808 | $0 | 67,893 (Direct) |
View |
Ownership |
2023-03-03 4:09 pm |
2024-02-28 2033-02-27 |
NovoCure Ltd | NVCR | Ocean Allyson J Director |
0 | $0 | 13,989 (Direct) |
View |
| 2023-02-28 Option Award |
2023-03-02 5:01 pm |
N/A N/A |
NovoCure Ltd | NVCR | Leonard Frank X President, CNS Cancers US |
18,621 | $0 | 94,066 (Direct) |
View |
| 2023-02-28 Option Award |
2023-03-02 5:01 pm |
2024-02-28 2033-02-27 |
NovoCure Ltd | NVCR | Leonard Frank X President, CNS Cancers US |
30,971 | $76.97 | 94,066 (Direct) |
View |
| 2023-02-28 Option Award |
2023-03-02 5:00 pm |
N/A N/A |
NovoCure Ltd | NVCR | Shah Pritesh Chief Growth Officer |
19,055 | $0 | 131,666 (Direct) |
View |
| 2023-02-28 Option Award |
2023-03-02 5:00 pm |
2024-02-28 2033-02-27 |
NovoCure Ltd | NVCR | Shah Pritesh Chief Growth Officer |
31,691 | $76.97 | 131,666 (Direct) |
View |
| 2023-02-28 Option Award |
2023-03-02 4:58 pm |
N/A N/A |
NovoCure Ltd | NVCR | Weinberg Uri Chief Innovation Officer |
12,992 | $0 | 77,885 (Direct) |
View |
| 2023-02-28 Option Award |
2023-03-02 4:58 pm |
2024-02-28 2033-02-27 |
NovoCure Ltd | NVCR | Weinberg Uri Chief Innovation Officer |
21,607 | $76.97 | 77,885 (Direct) |
View |
| 2023-02-28 Option Award |
2023-03-02 4:56 pm |
N/A N/A |
NovoCure Ltd | NVCR | Ben Arye Barak General Counsel |
17,755 | $0 | 64,438 (Direct) |
View |
| 2023-02-28 Option Award |
2023-03-02 4:56 pm |
2024-02-28 2033-02-27 |
NovoCure Ltd | NVCR | Ben Arye Barak General Counsel |
29,531 | $76.97 | 64,438 (Direct) |
View |
| 2023-02-28 Option Award |
2023-03-02 4:55 pm |
N/A N/A |
NovoCure Ltd | NVCR | Cordova Ashley Chief Financial Officer |
23,818 | $0 | 135,676 (Direct) |
View |
| 2023-02-28 Option Award |
2023-03-02 4:55 pm |
2024-02-28 2033-02-27 |
NovoCure Ltd | NVCR | Cordova Ashley Chief Financial Officer |
39,614 | $76.97 | 135,676 (Direct) |
View |
| 2023-02-28 Option Award |
2023-03-02 4:51 pm |
N/A N/A |
NovoCure Ltd | NVCR | Burke William Patrick Chief Human Resources Officer |
12,125 | $0 | 87,132 (Direct) |
View |
| 2023-02-28 Option Award |
2023-03-02 4:51 pm |
2024-02-28 2033-02-27 |
NovoCure Ltd | NVCR | Burke William Patrick Chief Human Resources Officer |
20,168 | $76.97 | 87,132 (Direct) |
View |
| 2023-02-28 Option Award |
2023-03-02 4:49 pm |
N/A N/A |
NovoCure Ltd | NVCR | GROENHUYSEN WILHELMUS CM Chief Operating Officer |
21,653 | $0 | 220,628 (Direct) |
View |
| 2023-02-28 Option Award |
2023-03-02 4:49 pm |
2024-02-28 2033-02-27 |
NovoCure Ltd | NVCR | GROENHUYSEN WILHELMUS CM Chief Operating Officer |
36,013 | $76.97 | 220,628 (Direct) |
View |
| 2023-01-06 Option Award |
2023-01-10 4:20 pm |
N/A N/A |
NovoCure Ltd | NVCR | Ben Arye Barak General Counsel |
150 | $62.3 | 17,152 (Direct) |
View |
| 2023-01-06 Option Award |
2023-01-10 4:18 pm |
N/A N/A |
NovoCure Ltd | NVCR | Cordova Ashley Chief Financial Officer |
66 | $62.3 | 74,442 (Direct) |
View |
| 2023-01-06 Option Award |
2023-01-10 4:17 pm |
N/A N/A |
NovoCure Ltd | NVCR | GROENHUYSEN WILHELMUS CM Chief Operating Officer |
102 | $62.3 | 165,126 (Direct) |
View |
| 2023-01-06 Option Award |
2023-01-10 4:14 pm |
N/A N/A |
NovoCure Ltd | NVCR | Benaim Ely Chief Medical Officer |
98 | $62.3 | 28,770 (Direct) |
View |
| 2023-01-06 Option Award |
2023-01-10 4:13 pm |
N/A N/A |
NovoCure Ltd | NVCR | Burke William Patrick Chief Human Resources Officer |
108 | $62.3 | 55,594 (Direct) |
View |
| 2023-01-05 Exercise |
2023-01-09 6:24 pm |
N/A 2029-03-21 |
NovoCure Ltd | NVCR | Weinberg Uri Chief Science Officer |
1,946 | $0 | 45,232 (Direct) |
View |
| 2023-01-05 Exercise |
2023-01-09 6:24 pm |
N/A N/A |
NovoCure Ltd | NVCR | Weinberg Uri Chief Science Officer |
1,946 | $47.04 | 45,232 (Direct) |
View |
| 2023-01-05 Exercise |
2023-01-09 6:21 pm |
N/A N/A |
NovoCure Ltd | NVCR | Leonard Frank X President, CNS Cancers US |
7,500 | $11.46 | 74,299 (Direct) |
View |
| 2023-01-05 Exercise |
2023-01-09 6:21 pm |
N/A 2025-02-23 |
NovoCure Ltd | NVCR | Leonard Frank X President, CNS Cancers US |
35,209 | $0 | 74,299 (Direct) |
View |
| 2023-01-05 Exercise |
2023-01-09 6:21 pm |
N/A N/A |
NovoCure Ltd | NVCR | Leonard Frank X President, CNS Cancers US |
7,183 | $21.15 | 74,299 (Direct) |
View |
| 2023-01-05 Exercise |
2023-01-09 6:21 pm |
N/A N/A |
NovoCure Ltd | NVCR | Leonard Frank X President, CNS Cancers US |
7,826 | $14.37 | 74,299 (Direct) |
View |
| 2023-01-05 Exercise |
2023-01-09 6:21 pm |
N/A N/A |
NovoCure Ltd | NVCR | Leonard Frank X President, CNS Cancers US |
5,517 | $7.15 | 74,299 (Direct) |
View |
| 2023-01-06 Option Award |
2023-01-09 6:18 pm |
N/A N/A |
NovoCure Ltd | NVCR | Danziger Asaf Chief Executive Officer |
39 | $62.3 | 13,622 (Direct) |
View |
| 2023-01-05 Exercise |
2023-01-09 6:18 pm |
N/A N/A |
NovoCure Ltd | NVCR | Danziger Asaf Chief Executive Officer |
25,000 | $11.46 | 13,622 (Direct) |
View |
| 2023-01-05 Exercise |
2023-01-09 6:18 pm |
N/A 2026-02-24 |
NovoCure Ltd | NVCR | Danziger Asaf Chief Executive Officer |
212,500 | $0 | 13,622 (Direct) |
View |
| 2023-01-05 Exercise |
2023-01-09 6:18 pm |
N/A N/A |
NovoCure Ltd | NVCR | Danziger Asaf Chief Executive Officer |
187,500 | $7.15 | 13,622 (Direct) |
View |
| 2022-12-02 Exercise |
2022-12-05 4:33 pm |
N/A 2027-02-21 |
NovoCure Ltd | NVCR | Cordova Ashley Chief Financial Officer |
2,000 | $7.15 | 82,128 (Direct) |
View |
| 2022-11-01 Option Award |
2022-11-03 4:42 pm |
N/A N/A |
NovoCure Ltd | NVCR | Leonard Frank X President, CNS Cancers US |
6,830 | $0 | 62,065 (Direct) |
View |
| 2022-11-01 Option Award |
2022-11-03 4:42 pm |
2023-11-01 2032-10-31 |
NovoCure Ltd | NVCR | Leonard Frank X President, CNS Cancers US |
11,609 | $73.2 | 62,065 (Direct) |
View |